Research programme: antibacterials - BioPort
Alternative Names: Research programme: benzazepines - BioPortLatest Information Update: 30 Apr 2007
At a glance
- Originator Emergent BioDefense Operations Lansing
- Class Small molecules
- Mechanism of Action Signal transduction pathway inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Bacterial infections
Most Recent Events
- 30 Apr 2007 Discontinued - Preclinical for Bacterial infections in USA (unspecified route)
- 16 Jun 2003 The assets of Antex Biologics and Antex Pharma have been acquired by BioPort Corporation
- 13 May 2003 This programme is still in active development